Natixis Advisors LLC Acquires 34,964 Shares of Sanofi (NASDAQ:SNY)

Natixis Advisors LLC increased its holdings in shares of Sanofi (NASDAQ:SNYFree Report) by 1.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 2,944,985 shares of the company’s stock after purchasing an additional 34,964 shares during the period. Natixis Advisors LLC owned approximately 0.12% of Sanofi worth $163,329,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in SNY. Eastern Bank increased its holdings in shares of Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares during the period. Bessemer Group Inc. grew its position in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after buying an additional 242 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company’s stock valued at $35,000 after acquiring an additional 545 shares during the period. UMB Bank n.a. raised its holdings in Sanofi by 30.7% in the 1st quarter. UMB Bank n.a. now owns 1,124 shares of the company’s stock valued at $62,000 after acquiring an additional 264 shares in the last quarter. Finally, Wayfinding Financial LLC acquired a new position in Sanofi in the 1st quarter valued at approximately $63,000. Institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of Sanofi stock opened at $49.35 on Wednesday. Sanofi has a 1-year low of $45.80 and a 1-year high of $60.12. The firm’s 50-day moving average price is $49.42 and its two-hundred day moving average price is $52.13. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $121.03 billion, a price-to-earnings ratio of 17.63, a P/E/G ratio of 1.13 and a beta of 0.48.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. BNP Paribas initiated coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price on the stock. Guggenheim reissued a “buy” rating on shares of Sanofi in a research note on Tuesday, June 3rd. Finally, Morgan Stanley set a $56.00 price target on shares of Sanofi in a research note on Monday, June 2nd. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has an average rating of “Buy” and an average price target of $62.00.

Read Our Latest Analysis on Sanofi

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.